Cargando…

250 Dosing and therapeutic drug monitoring of intravenous vancomycin in cystic fibrosis: A practice survey

Detalles Bibliográficos
Autores principales:	Dagenais, R., Su, V., Cen, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Cystic Fibrosis Society. 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527877/ http://dx.doi.org/10.1016/S1569-1993(22)00940-7

Ejemplares similares

1315. Ceftaroline Versus Vancomycin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis in Adults
por: Esquivel, Marc, et al.
Publicado: (2021)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

1329. Vancomycin Therapeutic Drug Monitoring: How to hit the Curve
por: Vala, Michael, et al.
Publicado: (2020)

Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application
por: Barber, Katie E., et al.
Publicado: (2016)

P17 Vancomycin therapeutic drug monitoring—a call for change?
por: Payne, Lara, et al.
Publicado: (2022)

1096. Evaluation of Vancomycin Pharmacokinetics in Intravenous Drug Users
por: Weihs, Sayo, et al.
Publicado: (2021)

487 Evaluating use of doxycycline versus vancomycin for treatment of methicillin-resistant Staphylococcus aureus–associated acute pulmonary exacerbations in people with cystic fibrosis
por: Brickel, K., et al.
Publicado: (2022)

In vitro evaluation of an intravenous microdialysis catheter for therapeutic drug monitoring of gentamicin and vancomycin
por: van der Mast, Jackelien E., et al.
Publicado: (2019)

182. Missed Opportunities to Discontinue Unnecessary Vancomycin During Pharmacist Therapeutic Monitoring
por: Medler, Corey J, et al.
Publicado: (2020)

235: COVID-19 vaccination in individuals with cystic fibrosis at a pediatric cystic fibrosis center
por: Elson, E., et al.
Publicado: (2021)

1108. Evaluation of Vancomycin Dosing in Adolescents
por: Weaver, Ashley I, et al.
Publicado: (2021)

Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients
por: Kim, Dae Il, et al.
Publicado: (2010)

Audit of therapeutic drug monitoring of dosing of vancomycin on an intensive care unit
por: Mason, P, et al.
Publicado: (2002)

P226 A survey of family experience of cystic fibrosis care during the COVID-19 pandemic
por: Watkinson, J., et al.
Publicado: (2021)

P111 Forced oscillation techniques – is it useful for the monitoring of adult patients with cystic fibrosis in the era of CFTR modulators
por: Markelić, I., et al.
Publicado: (2023)

44: Characterizing the COVID-19 pandemic among Canadians living with cystic fibrosis: A Canadian Cystic Fibrosis Registry study
por: Cheng, S., et al.
Publicado: (2021)

192. The Use of Area Under the Curve to Determine Therapeutic Vancomycin Dosing in Skin and Soft Tissue Infections
por: Dea, Lauren, et al.
Publicado: (2020)

51 Outcomes after SARS-CoV-2 infection in Canadians with cystic fibrosis: Analyses using the Canadian Cystic Fibrosis Registry
por: Cheng, S., et al.
Publicado: (2022)

P220 Experiences of virtual cystic fibrosis clinics during the COVID-19 pandemic at one UK adult cystic fibrosis centre
por: Warnock, L., et al.
Publicado: (2021)

P232 The impact of COVID-19 on the relationships between parents of young people diagnosed with cystic fibrosis and the cystic fibrosis multidisciplinary team
por: Jones, S., et al.
Publicado: (2021)

P146 COVID-19 pandemic in the Belgian cystic fibrosis patients compared with the international cystic fibrosis patients and the general Belgian population
por: Daneau, G., et al.
Publicado: (2023)

P135 SARS-COV-2 infection in patients with cystic fibrosis
por: Balanetchi, L., et al.
Publicado: (2021)

P088 Impact of COVID-19 and cocooning on employment of people with cystic fibrosis
por: Bhatnagar, R., et al.
Publicado: (2021)

P090 A UK survey on changes in managing people with cystic fibrosis during the COVID-19 pandemic
por: Hameed, M.S., et al.
Publicado: (2021)

346: Tennessee cystic fibrosis clinical care during the COVID-19 pandemic
por: Cacho, F., et al.
Publicado: (2021)

Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets
por: Bradley, Nicole, et al.
Publicado: (2023)

Vancomycin prescribing and therapeutic drug monitoring: Challenges of real clinical practice
por: Abdel Jalil, Mariam Hantash, et al.
Publicado: (2023)

Evaluation of Therapeutic Vancomycin Monitoring in Taiwan
por: Chen, Tzu-Ting, et al.
Publicado: (2022)

2226. Trough- Versus AUC-Based Vancomycin Monitoring for Treatment of Acute Pulmonary Exacerbations of Adult Cystic Fibrosis Patients
por: Smith, Darrell, et al.
Publicado: (2023)

P087 Impact of COVID-19 on mental health of children with cystic fibrosis and their parents
por: Bhatnagar, R., et al.
Publicado: (2021)

Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review
por: Dagenais, Renée V. E., et al.
Publicado: (2020)

P163 Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany
por: Dolce, D., et al.
Publicado: (2021)

Comparison of Vancomycin Pharmacokinetics in Cystic Fibrosis Patients Pre and Post-lung Transplant
por: White, Shannon, et al.
Publicado: (2020)

666 Ivacaftor boosts cystic fibrosis transmembrane conductance regulator–mediated nasal potential difference in cystic fibrosis transmembrane conductance regulator knockout mice treated with human cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid lipid nanoparticle
por: Mukherjee, A., et al.
Publicado: (2022)

418: Linezolid-resistant Staphylococcus aureus in patients with cystic fibrosis
por: Pitcher, N., et al.
Publicado: (2021)

P085 Impact of COVID-19 on hospital services and specialist care of adults with cystic fibrosis
por: Bhatnagar, R., et al.
Publicado: (2021)

276: Effects of COVID-19 pandemic on adult cystic fibrosis patients’ mental health
por: Chen, P., et al.
Publicado: (2021)

P084 The impact of the SARS-CoV-2 pandemic on people living with cystic fibrosis in Ireland: real-world data from the Irish cystic fibrosis registry
por: Rees, H., et al.
Publicado: (2021)

333: Perceptions of telehealth of patients with cystic fibrosis and their caregivers during the COVID-19 pandemic in Australia
por: Ruseckaite, R., et al.
Publicado: (2021)

232. Safety and Effectiveness of Intravenous to Oral De-escalation Compared to Continued Vancomycin Therapy in Orthopedic Infections
por: Gallagher, Chanah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_66ntks3i27gtso1tp6ouv3uk00